Project
Ibritumomab tiuxetan and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy. A multicenter phase I trial
Completed · 2006 until 2010
Hitz Felicitas, Demmer-Steingruber Ruth
Type
Range
Units
Status
Start Date
End Date
Financing
Study Design
Keywords
Partner
Brief description/objective
Identification of the maximum tolerated dose (MTD) of melphalan in combination with ibritumomab tiuxetan in patients ≥ 65 years with relapsed or chemotherapy resistant CD20+ lymphoma.
Evaluation of feasibility and safety of ibritumomab tiuxetan and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in the same patient population.
Additional research question: Feasibility of stem cell mobilization with vinorelbine in patients ≥ 65 years with lymphoma after salvage treatment.